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Summary
Objective: To examine the effects of anterior cruciate ligament (ACL) insufﬁciency, and subsequent bisphosphonate (BP) antiresorptive
therapy, on the bone mineral interface at the enthesis of remaining ligamentous restraints.
Methods: We measured bone mineral geometry (and subsequent adaptation) at the medial collateral ligament (MCL) origin, using micro-
computed tomography (mCT). Groups of normal control, 6 and 14 wk anterior cruciate ligament transected (ACLX), and 6 wk ACLXeBP
(risedronate) dosed rabbits were evaluated. Samples were then processed histologically, and the results of mineral adaptation and
progression of osteoarthritis (OA) compared to joint laxity values obtained from previous biomechanical testing of the MCL-complex.
Results: mCT deﬁned the MCL origin as a symmetrical, metaphyseal depression that contained soft-tissue elements, including ﬁbrocartilage
and ligamentdas seen in subsequent histological sections. In contrast, the insertions from ACLX animals lost signiﬁcant bone mineral, with an
MCL-insertion volume 1.2 times that of normal controls at 6 wk ACLX, which further increased to 2.3 times that of normal controls at 14 wk
ACLX. Signiﬁcant differences were also measured between 6 and 14 wk ACLX and age-matched normal controls in volume of cortical bone
containing the MCL insertion. However, there were no signiﬁcant differences in the percentage of cortical bone to underlying trabecular bone
at the MCL insertion. When comparing mCT mineral adaptation at the MCL-enthesis with historical MCL-complex laxity data, the values for
laxity after ACLX increased proportionately as bone mineral at the insertion was lost, and subsequent use of the BP risedronate reduced both
mineral loss and MCL-complex laxity.
Conclusion: Compared to the untreated ACLX condition, administering bisphosphonate immediately after loss of the ACL conserved bone
mineral at the MCL enthesis, suggesting the potential to therapeutically inﬂuence joint-complex laxity and OA progression.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Following anterior cruciate ligament (ACL) rupture in the
knee, a rapid phase of periarticular bone loss often occurs,
prior to the subchondral sclerosis of end-stage osteoarthritis
(OA)1e3. That loss occurs, in part, as both trabecular and
cortical bone remodel to adapt to altered loading, but also
due to the reduced limb usage and related disuse
osteopenia. In animal ACL-transection (ACLX) models,
signiﬁcant decreases in femoral and tibial bone mineral
density (BMD) were measured for both dogs1 and rabbits4,
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Received 4 November 2004; revision accepted 18 April 2005.79particularly in periarticular cancellous bone. In human
studies, the loss of bone mineral in the initial stages after
ACL disruption has been well established5e7, and was
measured in the distal femur as a 21% decrease in BMD5.
As chronic knee instability (and progression in joint
passive laxity) often results in the boneeligament joint
complex after loss of the ACL8,9, we questioned whether the
loss of bone mineral at the ligament insertions (or entheses)
was a contributing factor to increased joint laxity. We have
recently shown that bisphosphonate (BP) antiresorptive
therapy can signiﬁcantly reduce passive laxity in the
boneemedial collateral ligament (MCL)ebone complex
after ACLX, suggesting that bone mineral adaptation at
the MCL insertion was inﬂuenced with antiresorptive
therapy10. We deﬁne MCL-complex laxity as the distance
between tension and compression of the femureMCLetibia
complex during axial loading.
Thus, the objective of this study was to assess in an OA
model whether antiresorptive therapy altered mineral loss at
the boneeligament insertion. We examined and quantiﬁed
the changes in bone mineral at the femoral origin of the
MCL, using micro-computed tomography (mCT). We also0
791Osteoarthritis and Cartilage Vol. 13, No. 9investigated whether short-term antiresorptive therapy (i.e.,
with risedronate BP) altered bone mineral changes at the
MCL enthesis.
Materials and methods
SAMPLES
A total of 28 samples, harvested from the medial femoral
condyle of age-matched 1 yr old skeletally mature New
Zealand White rabbits, were analyzed. All animals were
sourced from the same supplier (Riemens Fur Ranches, St.
Agathe, ON) and randomly divided into four groups.
We surgically transected the ACL in three experimental
groups of rabbits. The ﬁrst and second groups remained
untreated for 6 wk (nZ 8) and 14 wk (nZ 6), respectively,
and served as age-matched ACLX controls. The third group
was dosed (0.01 mg/kg s.c.) daily with risedronate BP for 6
wk (nZ 6). The ﬁnal group of rabbits was evaluated as age-
matched, unoperated normal controls (nZ 8).
Animals were sacriﬁced by barbiturate overdose, and the
femureMCLetibia complex was dissected free. The MCL
was completely transected in its midsubstance, leaving
a portion of the MCL at the surface of the insertion as
a landmark. The medial and lateral femoral condyles were
separated using a bandsaw, and the femoral epiphysis cut
in the transverse plane proximal to the patello-femoral
groove (Fig. 1). Samples were placed into a polystyrene
vial, capped to reduce dehydration, and held in an upright
position using a foam jig to standardize the transverse
scanning plane for subsequent samples.
MICRO-COMPUTED TOMOGRAPHY (lCT) OF CALCIFIED
MINERAL
The medial femoral condyle was scanned in its entirety,
using an X-ray microtomograph (mCT, SkyScan 1072,
Aartselaar, Belgium). The condyles were scanned at
100 kV through 180( with a rotation step of 0.9(. All
samples were scanned at 12! magniﬁcation that produced
serial cross-sectional images composed of isotropic
Fig. 1. Diagram illustrating isolation of the medial femoral condyle
(red dotted line), and the transverse plane of subsequent mCT
slices (green plane). The MCL insertion appeared as a cortical
depression.19.4 mm3 voxels. A low-pass Gaussian ﬁlter was used to
ﬁlter the raw image data to reduce noise, and a ﬁxed
threshold was used on all samples to extract the mineral-
ized tissue phase. The ﬁltered binary image data were then
exported to SCION IMAGE (Scion Image Pty Ltd, Frederick,
Maryland, USA) for 2-dimensional (2-D) morphometric
measures or to ANALYZE TM 4.0 (Mayo Clinic, Rochester,
MN, USA) for 3-dimensional volumetric rendering. Mea-
sured indices included cortical bone volume of the insertion,
MCL-insertion volume (i.e., space occupied by soft tissue),
and percentage of cortical bone to trabecular bone at the
MCL insertion.
MORPHOMETRIC MEASUREMENTS (FROM 2-D mCT IMAGES)
MCL-insertion volume
Lines were drawn parallel to the postero-medial and
antero-medial surfaces of the medial femoral condyle. The
points of intersection between these lines and the out-
ermost region of cortical bone containing the MCL insert
were connected. The area deﬁned by that line and the
cortical bone containing the MCL insert was deﬁned as the
MCL insert area. That process was repeated for every
section containing the MCL insertion, summed, and
multiplied by mCT section thickness to achieve MCL insert
volume. Peri-insertional accreted bone and osteophytes
were not included in measurements (Fig. 2).
Sampling of cortical bone volume and percentage
cortical/trabecular bone
Perpendicular to the line connecting the anterior and
posterior limits of the MCL insert in the transverse plane,
a line was extended from the deepest point of the MCL
insert. From this newly deﬁned intersection, an arc was
drawn 100( from the posterior-medial line, with a radius of
5.25 mm. The region of interest was deﬁned as the area
enclosed by this arc. The cortical bone within this arc was
separately deﬁned as a region of interest. The area deﬁned
by the cortical bone region of interest multiplied by section
thickness was deﬁned as the volume fraction of cortical
bone containing the MCL insert. The ratio of the volume of
cortical bone to the volume of the arc was deﬁned as the
percentage of cortical bone deﬁning the MCL insert. This
procedure was undertaken for the deepest point of the
insert, as well as the twentieth and fortieth sections both
proximally and distally to the deepest point of the insert. The
measurements from the ﬁve sections were summed.
HISTOLOGICAL ASSESSMENT OF FOCAL CARTILAGE
DEGRADATION
Following the 30 min mCT scans, bone samples were
ﬁxed in 10% neutral buffered formalin for 72 h. Following
decalciﬁcation in formic acid (Cal-Ex II, Fisher Scientiﬁc,
ON) for 1 wk, and dehydration in ETOH/xylene, samples
were parafﬁn embedded. Frontal sections (7 mm) were cut
using a rotary microtome, and stained using haematoxylin
and eosin and safranin-O/fast green, to examine the MCL
insertion tidemark characteristics and to grade articular
cartilage degradation. For all investigations, a modiﬁed
Mankin grading system11,12 (Table I) was used to character-
ize the superﬁcial surface structure, cellularity, Safranin-O
staining characteristics, and tidemark integrity. When
examining the histology, the single observer was blinded
as to the treatment.
792 M. R. Doschak et al.: Bone mineral loss at ligament enthesesFig. 2. Diagram demonstrating the intersects drawn to isolate the MCL insertion, for subsequent areal quantitation and volume determination.
For ACLX samples, osteophytes were excluded from the measurements. Osteophyte margins were readily discernible against the compact
cortical bone, when viewed on the high resolution CT scans.STATISTICAL ANALYSIS
Analysis of variance (ANOVA, SPSS for Windows) was
used to detect signiﬁcant main effects in the measured
variables. Post hoc comparisons were conducted using
Tukey’s test (SPSS for Windows), with a signiﬁcance level
of P! 0.05 used for all statistical tests. For non-parametric
measures, the KruskaleWallis ANOVA was used.
We conducted power calculations for bone-related
measures in our NZW rabbit model for both mechanical
Table I
Modified Mankin grading system used to assess the degree of
cartilage degradation between treatment groups
Modiﬁed Mankin grading system
Structure
Normal 0
Irregular 1
Pannus 2
Superﬁcial cellular absence 3
Cellular clusters 4
Fissures into calciﬁed layers 5
Disorganization 6
Cellular abnormalities
Normal 0
Hypercellularity 1
Clusters 2
Hypocellularity 3
Matrix staining
Normal 0
Reduced staining in radial layer 1
Reduced inter-territorial matrix 2
Only in pericellular matrix 3
Absent 4
Minimum scoreZ 0 (healthy cartilage). Maximum scoreZ 13
(degraded OA cartilage).and physiological parameters. Baseline data contrasting
normal control and 6 wk ACLX rabbits included bone
mineral density, and MCL-complex laxity. Those data
suggested a minimum population size of six per group
provided an acceptable margin of error to detect a signiﬁ-
cant difference with 95% conﬁdence for the related bone
indices.
Results
We measured signiﬁcant differences in the fraction
volume of cortical bone containing the MCL insertion
between age-matched normal controls (0.42G 0.04 mm3)
and both 6 wk ACLX (0.38G 0.03 mm3; PZ 0.047) and
14 wk ACLX (0.36G 0.05 mm3; PZ 0.02). That resulted in
signiﬁcantly decreasing cortical bone volume after ACLX.
Similarly, compared to normal unoperated controls, MCL-
insertional volume was signiﬁcantly greater in the ACLX
cohort at 6 wk (P! 0.04) (Figs. 3 and 4) and increased
further at 14 wk after ACLX (P! 0.02). When we dosed
ACLX animals daily with risedronate for 6 wk, however, the
loss of MCL-insertional bone was less and not signiﬁcantly
different from normal control animals. No signiﬁcant differ-
ences were measured in the percentage of cortical bone to
underlying trabecular bone beneath the MCL insertion,
between 6 wk and 14 wk ACLX and age-matched controls.
Three-dimensional rendering of the 2-D mCT scans
illustrated the degree of bony adaptation (entheseal de-
pression and peri-insertional osteophytosis) that occurred
after loss of the ACL (Fig. 5).
When examining histological sections of the MCL in-
sertion, tissue elements such as lamellar bone, ﬁbrocarti-
lage, and ligament substance were readily discernable, as
was the periosteal lining adjacent to the MCL insertion. A
shift in the calciﬁed tidemark was observed in 6 wk ACLX
animals, exposing a greater amount of non-mineralized,
eosinophilic-stained tissue (Fig. 6). That contrasted with
risedronate-dosed 6 wk ACLX animals, where the tidemark
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of mineralized tissue.
When comparing mCT mineral adaptation at the MCL-
enthesis with MCL-complex laxity values obtained from
previous biomechanical testing of the MCL-complex10, it
was evident that MCL-complex laxity values after ACLX
increased proportionately as bone mineral at the insertion
was lost (Fig. 7). Similarly, when risedronate BP was used
to reduce bone loss after ACLX, a signiﬁcant improvement
in MCL-complex laxity also resulted.
Data for laxity values were used from cohorts of rabbits
that had been mechanically tested in a previous study, as
mechanical testing of the MCL-complex in this investigation
may have compromised the sample for subsequent mCT
evaluation. Because our experimental design examined
differences in cohorts of age-matched skeletally mature
rabbits, however, that were sourced from the same supplier
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Fig. 3. Volume of the MCL insertion. Values are meansG SD.
ACLX, anterior cruciate ligament transected; rised, risedronate-
dosed.(and not in individual animals), measurements compared
across cohorts would remain valid.
When assessing articular cartilage/meniscal gross mor-
phology during dissection, deteriorative OA changes were
established in the periarticular tissues from all ACLX joints,
including signiﬁcant joint anterioreposterior (AeP) instabil-
ity, meniscal tearing, capsular thickening, and pronounced
osteophytosis. By 14 wk ACLX, that had progressed to the
full-thickness ﬁssure of cartilage, with the full-thickness,
focal loss of cartilage in some samples. In contrast, all
normal control joints were unremarkable, presenting with
macroscopically healthy joint structures. Those gross
observations were conﬁrmed with the histological evalua-
tion of the cartilage samples. All 6 wk ACLX joints scored
signiﬁcantly higher on the modiﬁed Mankin scale compared
to normal control tissues, with loss of staining and cellularity
in the superﬁcial cartilage layer, and cartilage ﬁbrillation in
many samples. The risedronate dosed 6 wk ACLX group
also scored signiﬁcantly higher on the modiﬁed Mankin
scale compared to normal control tissues, and were no
different to scores obtained from 6 wk ACLX animals
(Table II).
Discussion
Our investigation showed that early loss of periarticular
bone mineral, after ACL insufﬁciency, included loss at the
MCL insertion. Such alterations in ligamentebone mineral
interface could inﬂuence MCL mechanical functioning,
including boneeligamentebone complex laxity, as mea-
sured in a previous study10. This potentially identiﬁes
a novel mechanism for progressive joint laxity with time
after ACL deﬁciency, and therefore identiﬁes a new
therapeutic target for antiresorptive drug therapy. This
mechanism differs to the premise of using interventions to
reduce subchondral bone changes and bone sclerosis inFig. 4. Two-dimensional mCT images of exemplar medial femoral condyles, illustrating the MCL insertion (arrow) in time zero control, and
subsequent bone adaptation in 6 wk ACLX, 14 wk ACLX, and 6 wk ACLX-risedronate-dosed animals. Dashed lines denote sagittal cuts
dividing distal medial and lateral condyles (lateral condyle not shown).
794 M. R. Doschak et al.: Bone mineral loss at ligament enthesesFig. 5. Three-dimensional renderings of two-dimensional mCT images, from exemplar medial femoral condyles, illustrating the MCL-insertion
bony depression and bone adaptation in ACLX limbs.the initiation and progression of cartilage damage and
OA13,14.
Ligament midsubstance changes also contributed to
MCL-complex laxity in the ACL-deﬁcient joint. After ACL
insufﬁciency, the remaining ligaments rapidly demonstrated
the loss of creep recovery, as a result of increased ﬁber
recruitment to axial loading, with the accompanying loss of
microscopically visible crimp15,16. That resulted in the initial
increase in MCL-complex laxity that was measured in ACL-
deﬁcient joints at 6 wk. However, those ligament midsub-
stance changes also occurred in our risedronate-dosed
ACLX joints. Thus, any net difference in MCL-complex laxity
between ACLX and risedronate-dosed ACLX joints would
have been as a result of other contributing factors, such as
MCL-insertional changes in bone mineral.
With the loss of ACL-mediated joint restraint, the increase
in AeP joint motion, and increased axial loading of
remaining ligamentous restraints (medial and lateral collat-
eral ligaments, and the posterior cruciate ligament) is
a stimulus for the remodeling activation of adjacent bone.
Disuse osteopenia also contributes to the activation of bone
remodeling, providing a general periarticular stimulus.
Evidence of limb disuse is readily seen when comparing
limb muscle masses between the experimental and
contralateral limbs, with muscle mass in the injured limb
measuring an average of 87% that of the contralateral
control10.
As a result, bone mineral is resorbed periarticularly, but
also at the boneeligament entheses. The focal loss of
mineral at ligament insertions would increase the proportion
of soft tissue to mineralized tissue in the MCL-complex, and
inﬂuence deformation after load transmission and with
subsequent time-dependant viscoelastic recovery of the
soft tissues across this interface. Thus, the net result of
loading this structure with an increased soft-tissue compo-
nent would be an increase in measurable complex de-
formation after loading.
Loss of peri-entheseal bone mineral could also compro-
mise the mechanical strength of the underlying bone during
MCL tensile loading, which may lead to microdamage andmicrofracture of bone surrounding the enthesis. Indeed, we
have previously noted that femoral fracture avulsion (in-
stead of ligament midsubstance) was the most common
failure mode of the rabbit MCL-complex when mechanically
tested to failure 6 wk after ACLX, implying that bone was
the weakest material in the MCL-complex9,15. Another
possibility is that meniscal insertions into bone also lose
bone mineral at their enthesis, and such events would
predispose the menisci (and the entire joint) to increased
displacement, with the risk of damage through mechanical
manipulation or even traumatic injury.
An interesting ﬁnding in this investigation was that bone
mineral loss may be occurring from mineralized ﬁbrocarti-
laginous tissues, as well as from periarticular bone. The
distal femoral MCL insertion (i.e., origin) is ﬁbrocartilagi-
nous, with a discontinuous cement line separating ﬁbrocar-
tilage from mineralized ﬁbrocartilage and mineralized
lamellar bone17. The insertion is therefore comprised of
two mineralized layers, and both would have been detected
‘‘as one’’ in BMD evaluations using imaging modalities. The
two layers were indistinguishable when viewed by mCT in
cross-section, and appeared as the ‘‘cortical rim’’ of the
enthesis. The signiﬁcant increase in volume of the MCL
insertion suggested that the majority of insertion mineral
loss occurred from the mineralized ﬁbrocartilage. As such,
this measure indicates that bone mineral may be lost
through mechanisms other than osteoclast-mediated re-
sorption, but likely involves a combination.
Calciﬁcation is a process that would occur spontaneously
in tissues if it was not actively inhibited18. Indeed, many
proteins (such as matrix GLA protein (MGP)) interact
speciﬁcally with mineral in vivo to prevent such spontane-
ous calciﬁcation, of arteries in particular19. At the MCL
insertion, if the layer of ﬁbrocartilage secretes mediators
and inhibitors of calciﬁcation, the loss of the mineral may
represent a ‘‘mobilization’’ of loosely aggregated mineral
crystals, due to the changing balance of mineralization
inhibitors in response to injury. Alternatively, as the zone of
mineralized ﬁbrocartilage was thin (ranging from 100 to
300 mm), it may be possible that the acidic environment of
Fig. 6. Histological sections of the MCL insertion, stained with Safranin-O trichrome, illustrating the loss of basophilic-staining mineral at the
MCL-bone interface in ACLX limbs.adjacent osteoclastic resorption of bone focally mobilized
the mineral in the ﬁbrocartilage. For example, osteoclast
‘‘cutting cones’’ can leave resorptive channels up to 10 mm
in depth20 and 200e400 mm in width21.
However, this also opens the possibility that BPs may
participate in mineralization kinetics of remodeling bone.
Because risedronate BP conserved the MCL-insertion
volume, this suggested that it was involved with the bone
mineral changes. BPs block bone mineral resorption by
interfering with osteoclast function, but BPs also adsorb to
freshly exposed bone mineral, and bind to newly forming
hydroxyapatite crystals at bone remodeling sites22. It is
likely, therefore, that risedronate was incorporated into
newly forming osteophytes, which were apparent in all BP-
dosed ACLX joints (and untreated ACLX joints), compared
to the total absence of osteophytes in normal control joints.
We did not examine osteophytes in this study as they were
external and ectopic to the boneeligament interface being
investigated at the MCL-enthesis.
Depending on the class of BP used, physicocoupling with
calcium salts will either inhibit spontaneous mineralization
(e.g., etidronate, clodronatedﬁrst generation BPs) or mayMCL-INSERTION VOLUME wrt LAXITY
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Fig. 7. The relationship between the volume of bone mineral at the
MCL insertion with respect to MCL-complex laxity.
796 M. R. Doschak et al.: Bone mineral loss at ligament enthesespromote intramembranous bone formation (e.g., incadro-
nate23). Such diverse outcomes may partly explain the
differences witnessed in several studies that used various
bisphosphonate candidates in ACLX animal models of OA.
Using etidronate, Howell et al. reported a reduction in
expected joint pathology (and osteophytosis) in a canine
ACLX model 12 wk after injury24. However, Myers and
coworkers noted that the nitrogen-containing BP NE-10035
reduced bone turnover in the same model, but did not affect
developing osteophytosis25. Recent work in ACLX rats
suggested that alendronate reduced both the incidence and
area of osteophytes13. Thus, the effects of newer classes of
BPs on spontaneous intramembranous ossiﬁcation (in
association with OA pathogenesis) would require further
investigation, in light of the major role osteophytosis plays
in OA.
The effects of three different BP candidates (Risedronate,
Alendronate, and Etidronate) on osteoblastic activity were
recently studied26. High doses of Risedronate and Alendr-
onate almost totally inhibited alkaline phosphatase activity,
collagen synthesis, and calciﬁcation of rat ﬁbroblastic
colony forming units (CFU-f) in cell culture. However, lower
doses of the same BP candidates slightly increased the
formation of CFU-f, suggesting a mildly anabolic effect. In
contrast, Etidronate was neither inhibitory nor stimulatory
for the same osteoblast parameters. Thus, a better un-
derstanding is needed of how different BP candidates
inﬂuence not only bone resorption, but formation as
welldand ultimately, bone pathology.
Thus, compared to the untreated ACLX condition,
administering BP immediately after ACL damage conserved
periarticular bone in an early OA model. Furthermore, BP
treatment addressing bone loss at ligament insertions short-
term after ACL injurydand prior to reconstructiondhas the
potential to inﬂuence the rate of OA progression, but the
long-term, functional effects will need to be further examined.
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